The Quantellect read.As of Nov 19, 2026, 24 active firms cover Regeneron Pharmaceuticals Inc: 18 rate it Buy or better, 6 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $185.00 to $1030.00 (about 5.6x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $816.50 sits 14% below the current $945.28. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 15 to 18 over recent months. On the fundamentals, the Street sees consensus EPS building from about $15.89 next quarter toward $62.12 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS24 active firms
Buy
Strong Buy00%
Buy1875%
Neutral625%
Sell00%
Strong Sell00%
Based on 24 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$816.50
-13.6% downside
Average target across 18 active firms as of Nov 19, 2026 vs $945.29 current
Highest Target$1030.00
Average Target$816.50
Lowest Target$185.00
Detailed analyst forecasts for REGN
Showing 1–20 of 20 named analysts shown · 24 active firms in the rating projection
As of Nov 19, 2026, 18 of 24 active firms rate REGN a Buy (6 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
REGN EPS & revenue forecast
EPS · NEXT QUARTER
$15.89
Range $12.90 – $18.80 · 9 analysts · +68% YoY
Next period, 9 analysts expect Regeneron Pharmaceuticals Inc to earn $15.89 a share (range $12.90 – $18.80), versus $9.47 a year earlier. Full-year consensus is $69.01, growing to $62.12 the year after.
REVENUE · NEXT QUARTER
$4.6B
Range $4.1B – $4.9B · 9 analysts · +28% YoY
Revenue is expected to reach $4.6B (range $4.1B – $4.9B), +27.6% year-over-year. Full-year consensus is $18.8B, rising to $20.2B next year.
Top analysts covering Regeneron Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on REGN.
#1
Yatin Suneja
Guggenheim · Rank #84
Buy
$1030.00+9.0% to target
Overall win rate
50%
+ Follow
#2
Andrew Berens
Leerink Partners · Rank #162
Neutral
$641.00-32.2% to target
Overall win rate
53%
+ Follow
#3
Terence Flynn
Morgan Stanley · Rank #222
Neutral
$779.00-17.6% to target
Overall win rate
36%
+ Follow
#4
CS
Chris Schott
JP Morgan · Rank #287
Buy
$1050.00+11.1% to target
Overall win rate
41%
+ Follow
#5
RW
Robert Wasserman
Benchmark · Rank #388
Buy
$185.00-80.4% to target
Overall win rate
41%
+ Follow
REGN stock forecast FAQ
What is REGN's average 12-month price target?+
The 18 active firms with a live target average $816.50 for Regeneron Pharmaceuticals Inc over the next 12 months, ranging from a $1030.00 high to a $185.00 low, as of Nov 19, 2026.
Is REGN stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 24 active firms as of Nov 19, 2026, 18 rate it Buy or Strong Buy, 6 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for REGN?+
The Street-high target is $1030.00 (Guggenheim), and the Street-low is $185.00 (Benchmark). The average of all 18 active-firm targets is $816.50.
How many active Wall Street firms cover REGN?+
24 active firms have a recognized rating on Regeneron Pharmaceuticals Inc as of Nov 19, 2026, and 18 active firms carry a live 12-month price target.
Who is the most accurate analyst covering REGN?+
Among analysts who currently cover REGN, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #84). Their current call is Buy with a $1030.00 target.
What is Regeneron Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $15.89 per share (range $12.90 – $18.80) across 9 analysts. Full-year EPS is projected at $69.01, rising to $62.12 the following year.
How much revenue is Regeneron Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $4.6B (range $4.1B – $4.9B). Full-year revenue is projected at $18.8B, growing to $20.2B next year.
Have analysts been upgrading or downgrading REGN lately?+
As of Nov 19, 2026, 18 of 24 active firms rate REGN a Buy (6 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their REGN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.